Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity

Triple-negative breast cancers (TNBCs) are characterized by poor survival, prognosis, and gradual resistance to cytotoxic chemotherapeutics, like doxorubicin (DOX). The clinical utility of DOX is limited by its cardiotoxic and chemoresistant effects that manifest over time. To induce chemoresistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Biswas, Dipsikha, Slade, Logan, Duffley, Luke, Mueller, Neil, Dao, Khoi Thien, Mercer, Angella, Pakkiriswami, Shanmugasundaram, El Hiani, Yassine, Kienesberger, Petra C., Pulinilkunnil, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443725/
https://www.ncbi.nlm.nih.gov/pubmed/34526485
http://dx.doi.org/10.1038/s41420-021-00602-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443725/
https://www.ncbi.nlm.nih.gov/pubmed/34526485
http://dx.doi.org/10.1038/s41420-021-00602-0

Ejemplares similares